Internal Medicine
Latest news
324 articles · 20 / page
Support for Alcohol Control Policies Among US Alcohol Consumers
Many US adults who consume alcohol support policies like cancer warnings and advertising restrictions on alcohol, with demographic variations in support levels.
Evaluating Hypertonic Saline and Carbocisteine in Non-Cystic Fibrosis Bronchiectasis: Insights from the CLEAR Trial
This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive
Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors
A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.
Challenges and Insights in Sustaining Weight Loss: Evaluating Adaptive vs Static Support
A recent trial comparing adaptive, algorithm-driven telephone support with static monthly coaching found no significant difference in long-term weight loss maintenance, highlighting complexities in obesity treatment and the need for refined
The Hidden Purines in Plant-Based Diets: What High Uric Acid Patients Need to Know
High uric acid is linked to several diseases, and many avoid meat fearing purines. However, some vegetarian foods are high in purines too. Understanding these can help better manage uric acid levels and prevent complications like gout.
Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Evaluating Low-Dose Aspirin for Postpartum Venous Thromboembolism Prevention: Insights from the Pilot PARTUM Trial
The pilot PARTUM trial demonstrates the feasibility of a large-scale multi-national randomized study assessing low-dose aspirin versus placebo for postpartum venous thromboembolism prevention in moderate-risk individuals, supporting further
Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy
In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and
Ageing, Oral Microbiome, and Vascular Health: How Dietary Nitrate Unlocks Cardiovascular Benefits
Dietary nitrate supplementation alters age-related oral microbiome changes, enhancing nitric oxide bioavailability and reducing blood pressure in older adults, highlighting a novel mechanism for vascular health improvement.
Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome
Long COVID patients exhibit distinct mitochondrial bioenergetic impairments, with altered ATP synthase function correlating with clinical symptoms and quality of life, implicating mitochondrial dysfunction in its pathogenesis.
Browse by specialty
Open language-specific specialty feeds and department pages.